Luteinising hormone releasing hormone agonists (also called gonadotropin-releasing hormone agonists GnRH agonists) are agents used in the hormonal modulation of malignant and benign diseases including:
These agents may cause an initial stimulation in the secretion of luteinising hormone (LH) resulting in a "flare" in symptoms in patients with symptomatic prostatic cancer during the first 1-2 weeks of treatment.
After 1-2 weeks pituitary gonadotrophin secretion is down-regulated leading to inhibition of ovarian and testicular sex hormone production.
If a tumour flare is likely to cause problems e.g. spinal cord compression, then an antiandrogen should also be given at least 3 days before the LHRH agonist and continued concurrently for three weeks.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.